Find Clinical Trials & Studies

Visit the Research & Education Institute

Study of XL309 (ISM3091) in Patients With Advanced Solid Tumors

I'm Interested!

Please call
1-800-641-2422

An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors. EXEL 1Y24 (XL309-101)

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Solid Tumor

Study Purpose

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.

Principal Investigator
Sarah Lynam MD

Department/Division
Cancer (Any Solid Tumor)

UH IRB: STUDY20240329
StudyID: EXEL1Y24
ClinicalTrials.gov: NCT05932862

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422